Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections

April 17, 2018 updated by: University Research Co, LLC

Evaluation of the Performance of a Highly-sensitive Rapid Diagnostic Test (RDT) Versus Conventional RDT, Compared With PCR as the Gold Standard, in Reactive Case Detection of Malaria Infections in Rakhine State, Myanmar

A systematic review assessing the role, appropriateness and benefits of the active case detection strategy, both proactive and reactive, in low malaria transmission settings. A common indication is that more studies should be carried out to optimize the ACD strategy to the local context, or to provide evidence for the adoption of improved methods. One possible improved method is the use of more accurate diagnostic tools, such as the hsRDT proposed in this study, with an increased capacity to detect lower levels of parasitemia. It can provide a timely and relevant contribution for their development of national Standard Operating Procedures for a screening tool in the reactive case detection strategy.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

The study is conducted in the areas under Sakhanmaw Rural Health Center, Ann Township in Southern Rakhine State, Myanmar.

General objective was to evaluate the performance of the new highly-sensitive rapid diagnostic test (RDT) developed by SD Bioline versus conventional RDT, compared with PCR as the gold standard, in reactive case detection of malaria infections in Rakhine State, Myanmar.

Specific objectives

  • To evaluate the prevalence of malaria identified by the new hsRDT in comparison with that by cRDT and PCR
  • To assess the diagnostic performance characteristics of hsRDT versus cRDT, using PCR as gold standard, in the detection of P.falciparum infections
  • To evaluate correlation of detection capability between cRDT and hsRDT
  • To identify risk factors associated with malaria infection, including but not limited to, socio-demographic factors and travel history related with malaria index cases

This is a prospective community-based single-center reactive case detection (RCD) study to assess the performance of hsRDT versus cRDT in identifying individuals with malaria infection ("Secondary case") in a population living and/or working in a close physical proximity to an "index case." All cases parasitologically confirmed by conventional RDT will be promptly notified to the study team and interviewed with a standardized case investigation form at their home, possibly within 3 days. All members of the primary case household and those of the nearest 10 households, aged 5 years and above, will be invited to participate in the study. A blood spot will be collected for subsequent PCR analysis. At least 50 index cases are targeted for investigation and reactive case detection and an estimated number of 1,980 persons will be involved in the study.

It is expected that this study will be an important input for the national malaria control program in Myanmar as they develop the strategies to conduct reactive case detection.

A suitable statistical software, e.g. STATA will be used to analyze the data resulting from the participant interviews and 3 parasitological tests. Logistic regression models will be developed to examine factors significantly associated with malaria infections.

Study Type

Interventional

Enrollment (Anticipated)

1980

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Yangon, Myanmar
        • Recruiting
        • University Research Co., LLC (URC)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age at least 5 years old
  • Resident of the villages, or temporary visitors, or co-workers or co-travelers of index case
  • Willingness to participate in the study evident by informed consent

Exclusion Criteria:

  • Presence of severe clinical illness including severe malaria
  • Non-resident index cases
  • Refusal to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Diagnostic performance of hsRDT
Comparing diagnostic power of two diagnostics
Testing highly sensitive RDT detection for low parasitemia
Other Names:
  • Highly sensitive RDT is also used as ultrasensitive RDT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of malaria infections identified by the new hsRDT
Time Frame: PCR diagnosis of samples will occur after 10 months of data collection.
Outcomes measured by malaria test positivity rate by cRDT, hsRDT and PCR, respectively
PCR diagnosis of samples will occur after 10 months of data collection.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic performance characteristics of hsRDT versus cRDT using PCR as gold standard, in the detection of P.falciparum infections
Time Frame: Outcomes will be analyzed after 10 months of data collection
Outcomes measured between hsRDT and cRDT
Outcomes will be analyzed after 10 months of data collection
Correlation of detection capability between cRDT and hsRDT
Time Frame: PCR results will be analyzed during month 10
Outcomes measured by correlation of test positivity rates
PCR results will be analyzed during month 10
Risk factors associated with malaria infection cases
Time Frame: Outcome will be measured/analyzed in month 10, after PCR results are released
Outcomes will be measured by relative risk of malaria in association with different risk factors identified
Outcome will be measured/analyzed in month 10, after PCR results are released

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Saw Lwin, MD, University Research Co, LLC
  • Study Chair: Feliciano Monti, MD, US Embassy, Yangon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 2, 2017

Primary Completion (ANTICIPATED)

June 28, 2018

Study Completion (ANTICIPATED)

October 1, 2018

Study Registration Dates

First Submitted

March 19, 2018

First Submitted That Met QC Criteria

April 17, 2018

First Posted (ACTUAL)

April 27, 2018

Study Record Updates

Last Update Posted (ACTUAL)

April 27, 2018

Last Update Submitted That Met QC Criteria

April 17, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • HP-00076579
  • Pro00089928 (OTHER: Duke University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malaria,Falciparum

3
Subscribe